Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT06181149 Recruiting - Healthy Subjects Clinical Trials

Auditory Prediction and Error Evaluation in the Speech of Individuals Who Stutter

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Stuttering negatively impacts communication and reduces the overall quality of life and well-being of individuals who stutter. This study will provide a strong foundation for developing neural and behavioral interventions for stuttering. Participants will be asked to name pictures, read words/sentences silently or aloud, and listen to speech and nonspeech sounds while their speech, muscle, and brain signals are collected. Some participants may also receive brain stimulation while reading and speaking.

NCT ID: NCT06162169 Recruiting - Healthy Subjects Clinical Trials

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Start date: November 25, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole, rifampicin, and omeprazole in healthy subjects.

NCT ID: NCT06153758 Recruiting - Healthy Subjects Clinical Trials

Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults

Start date: November 27, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults.

NCT ID: NCT06145646 Recruiting - Healthy Subjects Clinical Trials

Intramuscular Temperature on the Echo-textural Characteristics

Start date: November 30, 2023
Phase: N/A
Study type: Interventional

Echointensity and echotexture have been used as a physiological marker for changes in skeletal muscle quality and structure caused by physical training, low activity, ageing and some neuromuscular disorders. However, there are some influencing factors on muscle echo-intensity and echotexture, such as temperature, which may not be taken into account when performing an ultrasound assessment and may alter the results. This study aims to investigate the effects of muscle temperature on echointensity and other 2nd order echotextures variables such as homogeneity, contrast, correlation and entropy of muscle tissue, in order to gain a better understanding of this correlation and minimise its influence, which would allow greater precision in the use of muscle ultrasound as a diagnostic tool. The methodology of this study includes firstly the acquisition of ultrasound images of the vastus lateralis muscle. This acquisition will be performed during the continuous recording of muscle temperature, carried out during a passive cooling process after 20 min of heating using microwave equipment. In addition, to standardise the results, a correction factor will be calculated to compensate for the influence of subcutaneous adipose tissue thickness on echogenicity and echotexture.

NCT ID: NCT06122272 Recruiting - Healthy Subjects Clinical Trials

An Exploratory Trial in Hong Kong to Explore the Effect of a New Formula

Start date: December 19, 2023
Phase: N/A
Study type: Interventional

This is an exploratory study with the aim to gain insight and potentially generate hypotheses on health benefits of feeding with study product. This study explores in healthy subjects the effect of feeding with the test product compared to the control product in early life.

NCT ID: NCT06089837 Recruiting - Healthy Subjects Clinical Trials

Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects

Start date: November 28, 2023
Phase: Phase 1
Study type: Interventional

EC5026 has been shown to be effective in preclinical pain models of pain, including inflammatory and neuropathic pain subtypes. Two Phase 1a studies - a Phase 1a single ascending dose (SAD) study and a Phase 1a fed-fasted study - have been conducted, evaluating the safety, tolerability, PK, and food effects of single oral doses of EC5026 ranging 0.5 to 24 mg. The present study will evaluate the safety, tolerability, and PK of 2 sequential ascending dose regimens of EC5026, administered once daily for 7 consecutive days, in healthy volunteers.

NCT ID: NCT06076044 Recruiting - Healthy Subjects Clinical Trials

Effects of Transcranial Oscillatory Direct Current Stimulation on the Functions of Cerebral Cortex in Healthy Subjects

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

To investigate the effect of transcranial oscillatory direct current stimulation on functions of cerebral cortex (cortical excitability and frequency of eeg) in healthy subjects

NCT ID: NCT06070857 Recruiting - Healthy Subjects Clinical Trials

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers

Start date: October 5, 2023
Phase: Phase 1
Study type: Interventional

The study consists of 10 dose groups, 8 subjects in each group (male or female), randomly assigned to study drug or placebo group to evaluate the safety, tolerability and pharmacokinetics characteristics.

NCT ID: NCT06040918 Recruiting - Healthy Subjects Clinical Trials

Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Start date: October 4, 2023
Phase: Phase 1
Study type: Interventional

This is phase 1 single cohort study evaluating the effects of N-803 administration on mononuclear cells (MNC) collected from healthy donors undergoing a procedure called apheresis.

NCT ID: NCT06014515 Recruiting - Clinical trials for Cardiovascular Disease

Single-tracer Multiparametric PET Imaging

Start date: February 14, 2024
Phase: Early Phase 1
Study type: Interventional

The overarching goal of this project is to develop and evaluate a single-tracer multiparametric positron emission tomography (PET) imaging solution for simultaneous imaging of blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG) alone. The investigators working hypothesis is that quantitative blood flow can be extracted from dynamic 18F-FDG PET data by use of tracer kinetic modeling, in addition to glucose metabolism that 18F-FDG is conventionally used for.